(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 December 2006 (07.12.2006)

PCT

(10) International Publication Number
WO 2006/129859 A3

(51) International Patent Classification:
A61K 31/366 (2006.01) *A61K 45/06* (2006.01)
A61K 31/397 (2006.01) *A61P 1/16* (2006.01)
A61K 31/40 (2006.01) *A61P 3/06* (2006.01)
A61K 31/553 (2006.01)

(21) International Application Number:
PCT/JP2006/311362

(22) International Filing Date: 31 May 2006 (31.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/685,871 1 June 2005 (01.06.2005) US
60/728,329 20 October 2005 (20.10.2005) US

(71) Applicant *(for all designated States except US)*: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-Chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NISHIMOTO, Tomoyuki** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP). **TOZAWA, Ryuichi** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP). **WADA, Takeo** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP). **ISHIKAWA, Eiichiro** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP). **NISHI, Toshiya** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP). **IINO, Hiroko** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 5328686 (JP).

(74) Agents: **KAWAMIYA, Osamu** et al.; AOYAMA & PARTNERS, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka 5400001 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
19 April 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATIONS OF A SQUALENE SYNTHASE INHIBITOR AND A HMG-COA REDUCTASE INHIBITOR FOR TREATING HYPERLIPIDEMIA

(57) Abstract: A pharmaceutical composition useful for the prevention and/or treatment of hyperlipidemia, which comprises combining an effective amount of a squalene synthase inhibitor and a HMG-CoA reductase inhibitor is provided. Furthermore, a method for preventing and / or treating hepatic toxicity caused by the administration of a HM6-C0A veductase inhibitor, which comprisis adminisvering an effective amount of a sgualence synthase inhibitor, is provided .

WO 2006/129859 A3